Pediatric Dermatology Looks Bright as New Treatments Bring Hope Amid Access Challenges

The pediatric dermatology industry is undergoing a number of significant advancements across various skin conditions, with new treatments offering hope for children and adults affected by these conditions, according to Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital.

Eichenfield, who presented a session at the American Academy of Dermatology’s annual meeting in Orlando, discussed some of the most pressing topics in the field.

Atopic dermatitis continues to be a major focus, with the development of novel non-steroidal topical treatments and expanded use of biologics such as Dupixent (dupilumab).

In addition, newly approved biologics like Nemluvio (nemolizumab-ilto) and Ebglyss (lebrikizumab-lbkz) provide more treatment options for adults, raising concerns about their everyday use in medical care, Eichenfield shared.

Another area of progress includes vascular lesions.

Researchers have discovered genetic differences that set hemangioma-like growths apart from true malformations.

Eichenfield said this new understanding is changing how these conditions are classified and may lead to treatments that specifically target the underlying causes. It also helps doctors make more accurate diagnoses and could improve treatment options in the future.

Vitiligo, a condition that causes skin depigmentation, is also seeing new developments.

Updated guidelines for topical treatments have been introduced, and systemic therapies currently being tested in adults may soon be considered for pediatric use.

In acne treatment, recent research has provided new insights into severe forms such as acne fulminans, as well as a renewed discussion on the role of hormonal therapy.

Eichenfield added that hidradenitis suppurativa, a chronic inflammatory skin disorder, remains an area in need of innovation, as no new treatments have yet been approved for younger patients.

While these advancements are promising, access to treatment remains a major challenge, particularly due to high drug costs and insurance barriers, he said.

The challenges of the U.S. healthcare system often dictate which treatments patients can receive.

“The U.S. healthcare model is a difficult one, and every day in clinical practice, we're trying to figure out what we think is right for the patient, with the patient making their decision. Shared decision-making,” he said. “But someone else is influencing what we can get, and that happens to be who their insurer is and what their policy is.”

He added that the prior authorization process and insurance restrictions frequently delay or limit access to effective medications, placing an additional burden on both physicians and families.

Although these challenges exist, Eichenfield remains optimistic.

The introduction of innovative therapies has improved the ability to manage pediatric skin conditions, and with determination, dermatologists can help ensure patients receive the best possible care.